Fenobam

Last updated
Fenobam
Fenobam.svg
Names
Preferred IUPAC name
N-(3-Chlorophenyl)-N′-(1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)urea
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.165.052 OOjs UI icon edit-ltr-progressive.svg
MeSH Fenobam
PubChem CID
UNII
  • InChI=1S/C11H11ClN4O2/c1-16-6-9(17)14-10(16)15-11(18)13-8-4-2-3-7(12)5-8/h2-5H,6H2,1H3,(H2,13,14,15,17,18) X mark.svgN
    Key: DWPQODZAOSWNHB-UHFFFAOYSA-N X mark.svgN
  • InChI=1/C11H11ClN4O2/c1-16-6-9(17)14-10(16)15-11(18)13-8-4-2-3-7(12)5-8/h2-5H,6H2,1H3,(H2,13,14,15,17,18)
    Key: DWPQODZAOSWNHB-UHFFFAOYAC
  • O=C1CN(C)C(NC(NC2=CC=CC(Cl)=C2)=O)=N1
Properties
C11H11ClN4O2
Molar mass 266.684
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

Fenobam is an imidazole derivative developed by McNeil Laboratories in the late 1970s as a novel anxiolytic drug with an at-the-time-unidentified molecular target in the brain. Subsequently, it was determined that fenobam acts as a potent and selective negative allosteric modulator of the metabotropic glutamate receptor subtype mGluR5, [1] [2] and it has been used as a lead compound for the development of a range of newer mGluR5 antagonists. [3] [4] [5] [6]

Contents

Fenobam has anxiolytic effects comparable to those of benzodiazepine drugs, [1] [7] [8] but was never commercially marketed for the treatment of anxiety due to dose-limiting side effects such as amnesia and psychotomimetic symptoms. [9] [10] Following the discovery of its activity as a potent negative allosteric modulator of mGluR5, fenobam has been re-investigated for many applications, with its profile of combined antidepressant, anxiolytic, analgesic and anti-addictive effects potentially useful given the common co-morbidity of these symptoms. [11] [12] It has also shown promising initial results in the treatment of fragile X syndrome. [13] It was developed by a team at McNeil Laboratories in the 1970s. [14]

Chemistry

Fenobam is known to exist in five crystalline forms, all of them exhibiting a tautomeric structure with the proton attached to the five membered ring nitrogen. [15]

See also

Related Research Articles

<span class="mw-page-title-main">Metabotropic glutamate receptor 1</span> Mammalian protein found in humans

The glutamate receptor, metabotropic 1, also known as GRM1, is a human gene which encodes the metabotropic glutamate receptor 1 (mGluR1) protein.

<span class="mw-page-title-main">Metabotropic glutamate receptor 2</span> Mammalian protein found in humans

Metabotropic glutamate receptor 2 (mGluR2) is a protein that, in humans, is encoded by the GRM2 gene. mGluR2 is a G protein-coupled receptor (GPCR) that couples with the Gi alpha subunit. The receptor functions as an autoreceptor for glutamate, that upon activation, inhibits the emptying of vesicular contents at the presynaptic terminal of glutamatergic neurons.

<span class="mw-page-title-main">Metabotropic glutamate receptor 3</span> Mammalian protein found in humans

Metabotropic glutamate receptor 3 (mGluR3) is an inhibitory Gi/G0-coupled G-protein coupled receptor (GPCR) generally localized to presynaptic sites of neurons in classical circuits. However, in higher cortical circuits in primates, mGluR3 are localized post-synaptically, where they strengthen rather than weaken synaptic connectivity. In humans, mGluR3 is encoded by the GRM3 gene. Deficits in mGluR3 signaling have been linked to impaired cognition in humans, and to increased risk of schizophrenia, consistent with their expanding role in cortical evolution.

<span class="mw-page-title-main">Metabotropic glutamate receptor 4</span> Mammalian protein found in humans

Metabotropic glutamate receptor 4 is a protein that in humans is encoded by the GRM4 gene.

<span class="mw-page-title-main">Metabotropic glutamate receptor 5</span> Mammalian protein found in humans

Metabotropic glutamate receptor 5 is an excitatory Gq-coupled G protein-coupled receptor predominantly expressed on the postsynaptic sites of neurons. In humans, it is encoded by the GRM5 gene.

<span class="mw-page-title-main">LY-341495</span> Chemical compound

LY-341495 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as a potent and selective orthosteric antagonist for the group II metabotropic glutamate receptors (mGluR2/3).

<span class="mw-page-title-main">2-Methyl-6-(phenylethynyl)pyridine</span> Chemical compound

2-Methyl-6-(phenylethynyl)pyridine (MPEP) is a research drug which was one of the first compounds found to act as a selective antagonist for the metabotropic glutamate receptor subtype mGluR5. After being originally patented as a liquid crystal for LCDs, it was developed by the pharmaceutical company Novartis in the late 1990s. It was found to produce neuroprotective effects following acute brain injury in animal studies, although it was unclear whether these results were purely from mGluR5 blockade as it also acts as a weak NMDA antagonist, and as a positive allosteric modulator of another subtype mGlu4, and there is also evidence for a functional interaction between mGluR5 and NMDA receptors in the same populations of neurons. It was also shown to produce antidepressant and anxiolytic effects in animals, and to reduce the effects of morphine withdrawal, most likely due to direct interaction between mGluR5 and the μ-opioid receptor.

<span class="mw-page-title-main">MTEP</span> Chemical compound

3-( ethynyl)pyridine (MTEP) is a research drug that was developed by Merck & Co. as a selective allosteric antagonist of the metabotropic glutamate receptor subtype mGluR5. Identified through structure-activity relationship studies on an older mGluR5 antagonist MPEP, MTEP has subsequently itself acted as a lead compound for newer and even more improved drugs.

<span class="mw-page-title-main">ADX-47273</span> Chemical compound

ADX-47273 is a research pharmaceutical developed by Addex Therapeutics which acts as a positive allosteric modulator (PAM) selective for the metabotropic glutamate receptor subtype mGluR5. It has nootropic and antipsychotic effects in animal studies, and has been used as a lead compound to develop improved derivatives.

<span class="mw-page-title-main">SIB-1757</span> Chemical compound

SIB-1757 is a drug used in scientific research which was one of the first compounds developed that acts as a selective antagonist for the metabotropic glutamate receptor subtype mGluR5. It has anti-hyperalgesia effects in animals. SIB-1757 along with other mGluR5 antagonists has been shown to have neuroprotective and hepatoprotective effects, and it is also used to study the role of the mGluR5 receptor in brain development.

<span class="mw-page-title-main">SIB-1893</span> Chemical compound

SIB-1893 is a drug used in scientific research which was one of the first compounds developed that acts as a selective antagonist for the metabotropic glutamate receptor subtype mGluR5. It has anticonvulsant and neuroprotective effects, and reduces glutamate release. It has also been found to act as a positive allosteric modulator of mGluR4.

<span class="mw-page-title-main">CDPPB</span> Chemical compound

CDPPB is a drug used in scientific research which acts as a positive allosteric modulator selective for the metabotropic glutamate receptor subtype mGluR5. It has antipsychotic effects in animal models, and mGluR5 modulators are under investigation as potential drugs for the treatment of schizophrenia, as well as other applications.

<span class="mw-page-title-main">Ro67-4853</span> Chemical compound

Ro67-4853 is a drug used in scientific research, which acts as a selective positive allosteric modulator for the metabotropic glutamate receptor subtype mGluR1. It was derived by modification of the simpler compound Ro01-6128, and has itself subsequently been used as a lead compound to develop a range of potent and selective mGluR1 positive modulators.

<span class="mw-page-title-main">LY-487,379</span> Chemical compound

LY-487,379 is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR2. It is used to study the structure and function of this receptor subtype, and LY-487,379 along with various other mGluR2/3 agonists and positive modulators are being investigated as possible antipsychotic and anxiolytic drugs.

<span class="mw-page-title-main">CECXG</span> Chemical compound

CECXG (3'-ethyl-LY-341,495) is a research drug which acts as a potent and selective antagonist for the group II metabotropic glutamate receptors (mGluR2/3), with reasonable selectivity for mGluR3. While it is some five times less potent than LY-341,495 at mGluR3, it has 38x higher affinity for mGluR3 over mGluR2, making it one of the few ligands available that is able to distinguish between these two closely related receptor subtypes.

<span class="mw-page-title-main">CTEP</span> Chemical compound

CTEP (Ro4956371) is a research drug developed by Hoffmann-La Roche that acts as a selective allosteric antagonist of the metabotropic glutamate receptor subtype mGluR5, binding with nanomolar affinity and over 1000 times selectivity over all other receptor targets tested. In animal studies it was found to have a high oral bioavailability and a long duration of action, lasting 18 hours after a single dose, giving it considerably improved properties over older mGluR5 antagonists such as MPEP and fenobam.

<span class="mw-page-title-main">MGS-0039</span> Chemical compound

MGS-0039 is a drug that is used in neuroscientific research, which acts as a potent and selective antagonist for group II of the metabotropic glutamate receptors (mGluR2/3). It produces antidepressant and anxiolytic effects in animal studies, and has been shown to boost release of dopamine and serotonin in specific brain areas. Research has suggested this may occur through a similar mechanism as that suggested for the similarly glutamatergic drug ketamine.

<span class="mw-page-title-main">GRN-529</span> Chemical compound

GRN-529 is a drug that was developed by Wyeth as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5).

<span class="mw-page-title-main">MFZ 10-7</span> Chemical compound

MFZ 10-7 is a drug with potential applications in the treatment of addiction, which acts as a negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5). Others of the kind, namely MPEP & MTEP, are not considered to have translational potential for human use due to off-target effects and short half-lives. Drugs of this kind have been used to offset craving for drugs of abuse such as cocaine in in vivo animal administration models.

<span class="mw-page-title-main">AZD9272</span> Medication

AZD 9272 is a drug which acts as a selective antagonist for the metabotropic glutamate receptor subtype mGluR5. It was unsuccessful in human trials as an analgesic, but continues to be widely used in research especially as its radiolabelled forms.

References

  1. 1 2 Porter RH; Jaeschke G; Spooren W; et al. (November 2005). "Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity". J. Pharmacol. Exp. Ther. 315 (2): 711–21. doi:10.1124/jpet.105.089839. PMID   16040814. S2CID   386427.
  2. ↑ Marino, MJ; Conn, PJ (2006). "Glutamate-based therapeutic approaches: Allosteric modulators of metabotropic glutamate receptors". Current Opinion in Pharmacology. 6 (1): 98–102. doi:10.1016/j.coph.2005.09.006. PMID   16368268.
  3. ↑ Wållberg, A; Nilsson, K; Osterlund, K; Peterson, A; Elg, S; Raboisson, P; Bauer, U; Hammerland, LG; Mattsson, JP (2006). "Phenyl ureas of creatinine as mGluR5 antagonists. A structure-activity relationship study of fenobam analogues". Bioorganic & Medicinal Chemistry Letters. 16 (5): 1142–5. doi:10.1016/j.bmcl.2005.11.092. PMID   16380255.
  4. ↑ Ceccarelli, SM; Jaeschke, G; Buettelmann, B; Huwyler, J; Kolczewski, S; Peters, JU; Prinssen, E; Porter, R; et al. (2007). "Rational design, synthesis, and structure-activity relationship of benzoxazolones: New potent mglu5 receptor antagonists based on the fenobam structure". Bioorganic & Medicinal Chemistry Letters. 17 (5): 1302–6. doi:10.1016/j.bmcl.2006.12.006. PMID   17189691.
  5. ↑ Jaeschke, G; Porter, R; Büttelmann, B; Ceccarelli, SM; Guba, W; Kuhn, B; Kolczewski, S; Huwyler, J; et al. (2007). "Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists". Bioorganic & Medicinal Chemistry Letters. 17 (5): 1307–11. doi:10.1016/j.bmcl.2006.12.033. PMID   17196387.
  6. ↑ Gichinga, Moses G.; Olson, Jeremy P.; Butala, Elizabeth; Navarro, Hernán A.; Gilmour, Brian P.; Mascarella, S. Wayne; Carroll, F. Ivy (2011). "Synthesis and Evaluation of Metabotropic Glutamate Receptor Subtype 5 Antagonists Based on Fenobam". ACS Medicinal Chemistry Letters. 2 (12): 882–884. doi:10.1021/ml200162f. PMC   3328804 . PMID   22523618.
  7. ↑ Pecknold, JC; McClure, DJ; Appeltauer, L; Wrzesinski, L; Allan, T (1982). "Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study". Journal of Clinical Psychopharmacology. 2 (2): 129–33. doi:10.1097/00004714-198204000-00010. PMID   7042771.
  8. ↑ Goldberg, ME; Salama, AI; Patel, JB; Malick, JB (1983). "Novel non-benzodiazepine anxiolytics". Neuropharmacology. 22 (12B): 1499–504. doi:10.1016/0028-3908(83)90118-1. PMID   6142427. S2CID   44419672.
  9. ↑ Palucha, A; Pilc, A (2007). "Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs". Pharmacology & Therapeutics. 115 (1): 116–47. doi:10.1016/j.pharmthera.2007.04.007. PMID   17582504.
  10. ↑ Jacob W, Gravius A, Pietraszek M, Nagel J, Belozertseva I, Shekunova E, Malyshkin A, Greco S, Barberi C, Danysz W (May 2009). "The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning". Neuropharmacology. 57 (2): 97–108. doi:10.1016/j.neuropharm.2009.04.011. PMID   19426746. S2CID   207224547.
  11. ↑ Carroll, FI (2008). "Antagonists at metabotropic glutamate receptor subtype 5: Structure activity relationships and therapeutic potential for addiction". Annals of the New York Academy of Sciences. 1141: 221–32. doi:10.1196/annals.1441.015. PMID   18991960. S2CID   45268931.
  12. ↑ Montana MC, Cavallone LF, Stubbert KK, Stefanescu AD, Kharasch ED, Gereau RW (June 2009). "The mGlu5 antagonist fenobam is analgesic and has improved in vivo selectivity as compared to the prototypical antagonist MPEP". The Journal of Pharmacology and Experimental Therapeutics. 330 (3): 834–43. doi:10.1124/jpet.109.154138. PMC   2729799 . PMID   19515968.
  13. ↑ Berry-Kravis, E; Hessl, D; Coffey, S; Hervey, C; Schneider, A; Yuhas, J; Hutchison, J; Snape, M; et al. (2009). "A pilot open label, single dose trial of fenobam in adults with fragile X syndrome". Journal of Medical Genetics. 46 (4): 266–71. doi:10.1136/jmg.2008.063701. PMC   2658751 . PMID   19126569.
  14. ↑ US Patent 3983135 4-Oxo-2-imidazolidinylidene ureas
  15. ↑ Thomas, Sajesh P. (2012). "Polymorphism and tautomeric preference in fenobam and the utility of NLO response to detect polymorphic impurities". Chemical Communications. 48 (85): 10559–10561. doi:10.1039/C2CC34912D. PMID   23000909.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.